BioXell S.p.A. announces change in management
"Enrico Colli has contributed significantly to the successful development of our Company since he joined BioXell in 2002" commented Francesco Sinigaglia. "I would like to acknowledge the excellent work Enrico has done in setting up the clinical programs for Elocalcitol, our lead compound. Today, Elocalcitol has the potential to become the monotherapy of choice for the treatment of lower urinary tract symptoms (LUTS) and could target a significant portion of both, the OAB and BPH markets. We all wish Enrico well in his future endeavors."
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.